Recent reports demonstrated that SiFA-comprising PSMA inhibitors show a higher albumin binding and thus decelerated clearance kinetics, which results in increased tumor uptake, but also increased kidney retention [21,29], which correlated well with our observations because [177Lu]Lu-DOTA-rhCCK-18 also exhibited an elevated albumin binding in vitro. Here, FOLH1 is linked to neoplasm.